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BACKGROUND AND PURPOSE
The highly conserved tryptophan (W6.48) in transmembrane domain 6 of GPCRs has been shown to play a central role in
forming an active conformation in response to agonist binding. We set out to characterize the effect of this mutation on the
efficacy of two agonists at multiple signalling pathways downstream of the adenosine A3 receptor.
EXPERIMENTAL APPROACH
Residue W6.48 in the human adenosine A3 receptor fused to yellow fluorescent protein was mutated to phenylalanine and
expressed in CHO-K1 cells containing a cAMP response element reporter gene. The effects on agonist-mediated receptor
internalization were monitored by automated confocal microscopy and image analysis. Further experiments were carried out
to investigate agonist-mediated ERK1/2 phosphorylation, inhibition of [3H]-cAMP accumulation and β-arrestin2 binding.
KEY RESULTS
NECA was able to stimulate agonist-mediated internalization of the W6.48F mutant receptor, while the agonist HEMADO was
inactive. Investigation of other downstream signalling pathways indicated that G-protein coupling was impaired for both
agonists tested. Mutation of W6.48F therefore resulted in differential effects on agonist efficacy, and introduced signalling
pathway bias for HEMADO at the adenosine A3 receptor.
CONCLUSIONS AND IMPLICATIONS
Investigation of the pharmacology of the W6.48F mutant of the adenosine A3 receptor confirms that this region is important
in forming the active conformation of the receptor for stimulating a number of different signalling pathways and that
mutations in this residue can lead to changes in agonist efficacy and signalling bias.
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Introduction
GPCR are composed of seven transmembrane (TM) spanning
α-helices and are responsible for translating signals from the
extracellular milieu to intracellular responses. It is becoming
increasingly clear that not all agonists acting at a given GPCR
activate the same intracellular signals; different agonists
appear able to bias signalling in favour of a particular down-
stream pathway, including those that do not involve hetero-
trimeric G-proteins (Azzi et al., 2003; Baker et al., 2003;
Whalen et al., 2011). For example, compounds acting at the
β2-adrenoceptor (Baker et al., 2003; Wisler et al., 2007), para-
thyroid hormone receptor (Gesty-Palmer et al., 2006) or the
angiotensin 1A receptor (Wei et al., 2003) have been identi-
fied that preferentially activate non-G-protein signalling
through the β-arrestin pathway. Individual residues that may
be important in such biased signalling are beginning to be
identified. For instance, for the angiotensin II receptor, muta-
tion of residues within the DRY motif at the bottom of TM
helix 3 can result in the receptor no longer being able to
activate G-protein signalling, but which is still internalized
effectively in an agonist-dependent manner (Gaborik et al.,
2003; Wei et al., 2003).
Within the transmembrane helices there are a number of
residues that are highly conserved throughout the GPCR
superfamily. One important residue in TM6 is a tryptophan
(W6.48, according to the numbering of Ballesteros and Wein-
stein) that is located within a conserved CWxP motif, where
the presence of the proline residue introduces a kink into the
TM helix. Analysis of the purified thermostabilized turkey
β1-adrenoceptor has indicated that a bent conformation of
TM6 is required for the formation of the inactivating ‘ionic
lock’ (Moukhametzianov et al., 2011). Movement around this
kink is believed to be the basis for forming an active confor-
mation of the GPCR that can stimulate intracellular signalling
pathways. W6.48 has been proposed to have an important
role as part of a rotomer toggle switch formed in association
with F6.52, the rearrangement of which has been related to
the movement of TM6 upon receptor activation (Shi et al.,
2002; Schwartz et al., 2006; Nygaard et al., 2009; Tate and
Schertler, 2009) and the formation of aromatic interactions
with F5.47 following receptor activation (Nygaard et al.,
2009). Residue W6.48 has been mutated in a diverse range of
GPCRs, including the β2-adrenoceptor (Shi et al., 2002; Holst
et al., 2003), the muscarinic M3 receptor (Wess et al., 1993),
the bradykinin B2 receptor (Marie et al., 2001), bovine rho-
dopsin (Ridge et al., 1992), the 5-HT4 receptor (Pellissier et al.,
2009) and the ghrelin receptor (Holst et al., 2010) and,
although the resulting mutants have a variety of phenotypes,
it is clear that this residue is important for the formation of an
agonist-induced active receptor conformation.
Activation of many GPCRs can lead to β-arrestin binding
and sequestration of the receptor from the cell surface. The
longstanding view that internalization of a GPCR leads to
termination of receptor-mediated signalling has recently
been challenged with reports demonstrating that, in addition
to the role of β-arrestin in scaffolding activation of ERK
(Lefkowitz and Shenoy, 2005), some receptors can still signal
to the cAMP pathway even after receptor internalization
(Mullershausen et al., 2009; Boutin et al., 2012; Werthmann
et al., 2012). In contrast to its role in G-protein-mediated
signalling, the role of the TM6 toggle switch on agonist-
mediated receptor internalization has not been widely
explored.
The adenosine A3 receptor belongs to a family of four
GPCRs (A1, A2A, A2B and A3) (for receptor nomenclature see
Alexander et al., 2013; Fredholm et al., 2011) that all respond
to adenosine and may have pathophysiological roles in con-
ditions, such as cancer, ischaemia, cardiovascular disease and
inflammation, making them attractive drug targets. The A3
receptor couples predominantly to Gi/o family G-proteins,
causing an inhibition of adenylyl cyclase and a subsequent
reduction in intracellular cAMP levels. Previous studies of this
receptor have shown that mutation of W6.48 (W243 in the A3
receptor) results in a receptor that is unable to couple to
G-proteins in the presence of agonists (Gao et al., 2002). In
the present study, we have investigated whether disruption of
the rotomer toggle switch by mutation of this residue to
phenylalanine (W243F) affects the receptor’s ability to inter-
nalize after agonist challenge. Here, we demonstrate that
there are marked differences in the effect of this mutation on
the ability of the agonists NECA and HEMADO to signal to
second-messenger pathways and internalize the A3 receptor.
Methods
Generation of constructs used
cDNA encoding the full length human A3 receptor (Alexander
et al., 2013) was fused in-frame with yellow fluorescent
protein (YFP) that did not contain a methionine start signal
and subcloned into pcDNA3.1. The W243F mutation was
introduced into the A3 receptor gene using the QuikChange
site-directed mutagenesis kit (Agilent Technologies, Cheshire,
UK) and was confirmed by DNA sequencing. Full length A3
W243F-YFP was excised and subcloned into a native
pcDNA3.1 vector. To generate A3-vYc and A3 W243F-vYc con-
structs, YFP was excised from the required A3 receptor con-
taining constructs and replaced with cDNA encoding the
C-terminal residues 155-238 of the venus variant of YFP (vYc)
(Kilpatrick et al., 2010). To generate N-terminal SNAP-tagged
A3 and A3 W243F, the methionine start signal was removed
from cDNA encoding the full length A3 and subcloned into a
vector (pSEMS) containing a 5HT3-receptor-derived signal
sequence followed by the SNAP tag (New England Biolabs,
Ipswich, MA, USA).
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Cell culture, generation of stable cell lines
and transient transfections
CHO-K1 cells stably expressing a cAMP response element-
secreted placental alkaline phosphatase (CRE-SPAP) reporter
gene (CHO CRE-SPAP) under hygromycin selectivity and
CHO-K1 cells stably expressing β-arrestin2-vYnL (CHO
β-arrestin2-vYnL, a gift from Dr. N. Holliday, University of
Nottingham, Nottingham, UK) were maintained in DMEM/
F12 medium containing 10% FCS and 2 mM L-glutamine at
37°C in a humidified atmosphere of air/CO2 (19:1). To gen-
erate CHO CRE-SPAP cell lines that stably expressed A3-YFP
or A3 W243F-YFP and CHO β-arrestin2-vYnL cells lines
co-expressing A3-vYc or A3 W243F-vYnL, the appropriate
parental cell lines were transfected with the required DNA
using Lipofectamine according to the manufacturer’s instruc-
tions. Transfected cells were subjected to selective pressure for
2–3 weeks through the addition of 1 mg·mL−1 G418 to the
normal growth medium. After 2–3 weeks, the cells were
dilution-cloned to obtain cell lines originating from a single
cell. Cell lines were initially screened for YFP or bimolecular
fluorescence complementation (BiFC) fluorescence and CRE-
SPAP cells lines were subsequently tested in the CRE-SPAP
gene transcription assay. SNAP-tagged A3 and A3 W243F DNA
was transiently transfected into CHO CRE-SPAP using Fugene
HD according to the manufacturer’s instructions using a 3:1
Fugene : DNA ratio. Cells were transfected 24 h before use for
imaging experiments.
Confocal imaging
Live-cell BiFC imaging was performed on A3-vYc/β-arrestin2-
vYnL and A3 W243F-vYc/β-arrestin2-vYnL cells grown in
Nunc Labtek 8-well plates, and images obtained using a Zeiss
710 confocal microscope (Carl Zeiss GmbH, Jena, Germany)
fitted with a 63× plan-Apochromat NA1.4 Ph3 oil-immersion
objective. Live-cell imaging analysis was performed on A3-YFP
or A3 W243F-YFP CRE-SPAP cells and transiently expressed
SNAP-A3 or SNAP-A3 W243F grown in Nunc Labtek 8-well
plates, and images obtained using a Zeiss LSM5 Exciter con-
focal microscope (Carl Zeiss GmbH) fitted with a 63× plan-
Apochromat NA1.4 DIC oil-immersion objective. For both
YFP, BiFC and BG-AF488 label, a 488 nm argon laser was used
to excite the fluorophore and emission was detected using a
BP505-530 filter. Cells expressing the SNAP-tagged receptors
were labelled with 1 μM SNAP-surface BG-AF488 (New
England Biolabs) in DMEM/F12 medium for 30 min
at 37°C/5% CO2. Before all imaging experiments, normal
growth medium or medium containing BG-AF488 was
removed and cells were washed twice in HEPES-buffered
saline solution (HBSS; 25 mM HEPES, 10 mM glucose,
146 mM NaCl, 5 mM KCl, 1 mM MgSO4, 2 mM sodium pyru-
vate, 1.3 mM CaCl2) and fresh HBSS was added for analysis.
To induce BiFC or internalization of receptors, cells were
incubated for 60 min (YFP-tagged receptors) or 45 min
(SNAP-tagged receptors) at 37°C with 10 μM NECA or
HEMADO before imaging. Images of A3-YFP and A3 W243F-
YFP cells were taken with same pinhole diameter, laser power,
gain and offset to allow comparison of YFP fluorescence. To
obtain fluorescence intensity values, a region of interest was
drawn around the plasma membrane of 10 cells per image in
Zeiss AIM 4.2 software (Carl Zeiss GmbH).
Automated imaging of
receptor internalization
CHO β-arrestin2-vYnL cells expressing either A3-vYc or A3
W243F-vYc or CRE-SPAP cells stably expressing either A3-YFP
or A3 W243F-YFP were seeded into 96-well clear-bottomed,
black-walled 96-well plates (μclear base, Greiner Bio One,
Stonehouse, UK) and grown to confluency. Immediately
before experimentation, normal growth medium was re-
placed with serum-free medium. To generate concentration-
response curves, increasing concentrations of NECA or
HEMADO were added to the cells before incubation for
45 min (YFP cell lines) or 60 min (BiFC cell lines) at
37°C/5% CO2/95% air. To estimate the time course of inter-
nalization, cells were treated with 10 μM NECA or HEMADO
for 2.5–120 min. For experiments to estimate the affinity
dissociation constant of CA200645 at A3-YFP and A3 W243F-
YFP, cells were pretreated with 25 nM CA200645 for 30 min
at 37°C/5% CO2/95% air before the addition of increasing
concentrations of NECA for 45 min. Medium was removed
and cells were washed once in PBS. Cells were then fixed by
the addition of 3% paraformaldehyde solution in PBS for
20 min at room temperature. After fixing, cells were washed
twice in PBS, before staining of the cell nuclei with the cell
permeable dye H33342 (2 μg·mL−1 in PBS) for 20 min at
room temperature, followed by two additional washes with
PBS. Images were obtained using an ImageXpress Ultra con-
focal plate reader (Molecular Devices, Sunnyvale, CA, USA).
Four central images were obtained per well using a Plan
Fluor 40x NA0.6 extra-long working distance objective. BiFC
and YFP images were obtained by excitation with a 488 nm
laser line with emission collected through a 525–550 nm
band pass filter and H33342 images obtained by excitation
with a 405 nm laser line and emission collected through a
447–460 nm band pass filter. Granularity analysis was per-
formed on the resulting images using a granularity algo-
rithm within MetaXpress software (Molecular Devices,
Sunnyvale, CA, USA) and intensity above background was
set for each individual experiment (Kilpatrick et al., 2010).
Areas of internalized receptors were identified by granularity
analysis; granules were defined as having a diameter of
between 7 and 15 μm and nuclei as having a diameter of
between 6 and 9 μm, resulting in a measurement of the
granule count per cell for each image.
Fluorescence-based competition binding assay
A3-YFP or A3 W243F-YFP CRE-SPAP cells were seeded into a
96-well clear-bottomed, black-walled plate and grown to con-
fluency. On the day of analysis, normal growth medium was
removed and cells washed once with HBSS pre-warmed to
37°C. Fresh HBSS was added to each well and the required
concentration of NECA or HEMADO added in addition to
25 nM CA200645 and the cells incubated for 60 min,
37°C/5% CO2. Buffer was then removed from each well, cells
washed once in HBSS and fresh HBSS added at room tempera-
ture. Plates were immediately imaged using an ImageXpress
Ultra confocal plate reader, which captured four central
images per well using a Plan Fluor 40× NA0.6 extra-long
working distance objective. CA200645 was excited at 635 nm
and emission collected through a 640–685 nm band pass
filter. Total image intensity was obtained using a multiwave
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length cell scoring algorithm within MetaXpress software
(Molecular Devices).
CRE-SPAP gene transcription assay
A3-YFP or A3 W243F-YFP CRE-SPAP cells were grown to con-
fluence in 96-well plates. One day before analysis, normal
growth medium was removed from the cells and replaced
with serum-free medium (DMEM/F12 containing 2 mM
L-glutamine). Where applicable, PTx (100 ng·mL−1) was
added at this stage. On the day of the assay, the medium was
removed and replaced with fresh serum-free medium con-
taining the required concentration of the agonist, and cells
were incubated for 1 h at 37°C/5% CO2. After 1 h, the
required concentration of forskolin (FSK) was added, and cells
were incubated for a further 5 h at 37°C/5% CO2. Following
the 5 h incubation, all medium was removed from the cells,
40 μL of fresh serum-free medium was added to each well and
cells incubated for a further 1 h at 37°C/5% CO2. The plates
were then incubated at 65°C for 30 min, to destroy any
endogenous alkaline phosphatases. Plates were cooled to
room temperature and 100 μL of 5 mM 4-nitrophenyl phos-
phate in diethanolamine-containing buffer [10% (v v−1)
diethanolamine, 280 mM NaCl, 500 μM MgCl2, pH 9.85] was
added to each well; the plates were then incubated at 37°C for
25 min. The absorbance at 405 nm was measured using a
Dynex MRX plate reader (Chelmsford, MA, USA).
ERK1/2 phosphorylation assay
A3-YFP or A3 W243F-YFP CRE-SPAP cells were grown to con-
fluency in clear 96-well plates. Normal growth medium was
replaced with serum-free medium for at least 4 h before
analysis. Levels of ERK1/2 phosphorylation were measured
using the AlphaScreen SureFire p-ERK assay kit (PerkinElmer).
Briefly, cells were stimulated with the required concentration
of NECA for 5 min in fresh serum-free medium. Medium was
removed from each well and replaced with 40 μL SureFire
lysis buffer. After shaking for 5 min, a 1:80:20:120 v v−1 dilu-
tion of AlphaScreen beads : lysate : activation buffer : reac-
tion buffer in a 5.5 μL total volume was transferred to a white
opaque 384-well proxiplate in diminished light. After 2 h of
incubation in the dark at room temperature, the fluorescence
signal was measured with an EnVision plate reader (Perki-
nElmer) using standard AlphaScreen settings.
cAMP accumulation assay
A3-YFP or A3 W243F-YFP CRE-SPAP cells were grown to con-
fluence in 24-well plates. On the day of analysis, cells were
labelled with [3H]-adenine (2 μCi·mL−1) in a total volume of
600 μL per well for 2 h at 37°C/5% CO2 in normal growth
medium. After 2 h, the [3H]-adenine-containing medium was
removed; cells washed once in serum-free medium and fresh
serum-free medium, containing 10 μM rolipram, added. The
required concentration of agonist was added to the appropri-
ate well and cells incubated for 10 min at 37°C. After 10 min,
10 μM FSK was added to all wells, apart from basal wells, and
cells were incubated for a further 1 h at 37°C. The assay was
terminated by the addition of 50 μL concentrated HCl to
each well. The levels of [3H]-cAMP incorporated were meas-
ured by sequential Dowex and alumina chromatography and
the efficiency of each column was determined by the recovery
of [14C]-cAMP as described by Donaldson et al. (1988).
Data analysis
A basal and FSK control was included in each separate
concentration-response CRE-SPAP gene transcription assay
and cAMP accumulation assay to allow the responses in each
cell line to be expressed as an inhibition of FSK-stimulated
SPAP production. For ERK1/2 phosphorylation assays, data
were normalized to basal (in the absence of NECA) and the
maximal 10 μM NECA response. In NECA-induced internali-
zation assays, data were normalized to basal (in the absence
of NECA) and maximal internalization, and in assays using
HEMADO, data were normalized to basal (in the absence of
agonist) and a 10 μM NECA control which was included in
each separate experiment.
All data were fitted using non-linear regression in Prism 5
(GraphPad Software, San Diego, CA, USA). Concentration-
response curves were fitted to the following equation:
Response
E A
A EC
max
=
× [ ]
[ ] + 50
where Emax is the maximal response and the EC50 is the molar
concentration of agonist required to generate 50% of the Emax.
Time course experiments were fitted using a one phase asso-
ciation equation which is as follows
Y Y Plateau Y eo o Kt= + −( ) −( )−1
where Yo represents the level of internalization at time (t)
equal to zero, Plateau is the maximal internalization at
infinite time and K is the rate constant in min. Statistical
significance was determined by Student’s unpaired t-test or
by one-way ANOVA with Dunnett’s post hoc analysis and P <
0.05 was considered statistically significant. Competition
binding curves with the fluorescently labelled antagonists
CA200645 were fitted to the following equation to calculate
the binding affinity (Ki) NECA and HEMADO
K
IC
L
K
i
D
=
+
[ ]
50
1
where [L] is the concentration of CA200645 in nM, KD is the
KD of CA200645 at A3-YFP or A3 W243F-YFP in nM. The
calculated KD values used were 18.1 and 15.6 nM at A3-YFP
and A3 W243F-YFP respectively (Supporting Information
Figure S2). IC50 is calculated using the following equation
% inhibition of specific binding =
× [ ]
[ ] +
100
50
A
A IC
where [A] is the concentration of competing drug and the IC50
is the molar concentration of ligand required to inhibit 50%
of the specific binding of concentration [L] of CA200645.
Estimated affinity values (pKD) of CA200645 at A3-YFP and A3
W243F-YFP were calculated from the shift of the agonist
concentration-response curves elicited in the presence of a
single concentration of CA200645 (B = 25 nM) using the
following equation
DR
B
KD
= +
[ ]
1
where DR (dose ratio) is the ratio of the agonist concentration
required to evoke an identical response in the presence and
absence of antagonist, [B].
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Materials
G418, Lipofectamine and Optimem were obtained from Inv-
itrogen (Paisley, UK). FCS was obtained from PAA Laborato-
ries (Wokingham, UK), L-glutamine from Lonza (Basel,
Switzerland) and Fugene HD from Promega (Southampton,
UK). Pertussis toxin (PTx) was purchased from Merck Chemi-
cals (Nottingham, UK). NECA [5-(N-ethylcarboxamido)
adenosine] and HEMADO [2-(1-hexynyl)-N-methyladeno-
sine] were obtained from Tocris Bioscience (Bristol, UK). The
AlphaScreen SureFire p-ERK assay kit was obtained from
PerkinElmer (Waltham, MA, USA). [3H]-adenine and [14C]-
cAMP were from Perkin-Elmer (Buckinghamshire, UK).
CA200645 was purchased from Cellaura Technologies Ltd
(Nottingham, UK). All other chemicals and reagents were
purchased from Sigma-Aldrich (Gillingham, UK).
Results
Effect of W243F mutation in the A3 receptor
on agonist-stimulated receptor internalization
Previous studies have found that substitution of tryptophan
for phenylalanine at residue 243 in the A3 receptor (W243F)
resulted in a receptor that was unable to couple effectively to
heterotrimeric G-proteins (Gao et al., 2002). In the present
study, we have evaluated the impact of this mutation on
agonist mediated internalization, downstream signalling and
β-arrestin2 recruitment to two adenosine receptor agonists,
NECA and HEMADO (Figure 1B). To monitor receptor inter-
nalization, we generated CHO cell lines expressing either an
A3 receptor-YFP (A3-YFP) fusion protein or a fusion protein
containing the W243F mutation (A3 W243F-YFP). Confocal
imaging confirmed that both A3-YFP and A3 W243F-YFP were
predominantly expressed on the cell surface.
Treatment of both A3-YFP- and A3 W243F-YFP-expressing
cells with 10 μMNECA resulted in rapid internalization of the
receptor from the cell membrane to punctuate intracellular
granules, which accumulated predominantly in the perinu-
clear region (Figure 1A). In contrast, it was found that 10 μM
HEMADO-mediated substantial internalization of A3-YFP but
was unable to stimulate internalization of A3 W243F-YFP
(Figure 1A). Quantification of the fluorescence intensity at
the cell surface revealed that both NECA and HEMADO
stimulated 50% reduction in membrane fluorescence in
A3-YFP cells. In A3 W243F-YFP cells, a similar reduction in
membrane fluorescence was observed upon NECA treatment,
but there was no significant change in membrane fluores-
cence in the presence of HEMADO (Figure 1C), indicating
that minimal levels of A3 W243F-YFP are being removed from
the cell surface upon treatment with this agonist.
As the C-terminus of a GPCR plays an important role
in the interaction with intracellular proteins, such as
β-arrestins and GRKs, it may be that the fluorescent protein
fused to the C-terminus of the receptor is preventing the
interaction of the HEMADO-stimulated A3 W243F with these
adaptor proteins. To investigate this, the wild-type A3 recep-
tor and the equivalent W243F mutant, were labelled on
their N-terminus with a SNAP tag. These constructs were
transiently expressed in CHO CRE-SPAP cells and the SNAP
tag was subsequently labelled with the BG-AF488 surface
substrate to allow visualization of the receptors on the
surface of the transfected cells. Clear membrane expression
of SNAP-A3 and SNAP-A3 W243F were observed and treat-
ment of SNAP-A3-expressing cells with 10 μM NECA or
HEMADO resulted in clear punctate granules within the
cells. Whereas in cells expressing SNAP-A3 W243F, NECA
retained the ability to cause internalization of the receptor,
treatment with HEMADO did not result in any clear change
in the localization of the receptor from the cell surface (Sup-
porting Information Figure S1). These data suggest that the
differences observed with NECA and HEMADO are not due
to the C-terminal YFP tag.
To investigate the time- and concentration-dependence of
A3-YFP and A3 W243F-YFP internalization to both agonists,
quantification of internalized receptor was carried out using a
MD ImageXpress Ultra confocal plate reader. This high-
content screening based approach automatically collects
images from each well of a 96-well plate and quantifies the
accumulation of receptor in granules within the cells (pre-
dominantly in the perinuclear compartment) using a math-
ematical algorithm (Kilpatrick et al., 2010; Watson et al.,
2012). This enabled full concentration-response curves to
both NECA and HEMADO to be generated for A3-YFP and A3
W243F-YFP (Figure 2). NECA stimulated receptor internaliza-
tion with similar potency in the A3 W243F-YFP- and A3-YFP-
expressing cells (Figure 2A, Table 1). In contrast, HEMADO
stimulated internalization with a higher potency than NECA
at A3-YFP but did not stimulate any significant internalization
of the mutant A3 W243F-YFP receptor at concentrations up to
10 μM. These experiments were performed at a single time
point (45 min); therefore, to confirm that the observed
results were not due to slower kinetics of the HEMADO-
mediated response, the time course of internalization was
determined for both agonists. HEMADO-mediated internali-
zation of the wild-type A3-YFP was indeed significantly slower
than that observed with NECA (HEMADO t1/2 = 18.0 ± 4.8 min
vs. NECA t1/2 = 8.5 ± 0.8 min, P < 0.05, unpaired Student’s
t-test), but at the A3 W243F-YFP receptor, no accumulation of
internalized receptor could be detected even after 2 h stimu-
lation with 10 μM HEMADO (Figure 2C,D) and visual inspec-
tion of the images showed no change in receptor distribution
(data not shown). The difference in the kinetics of NECA- and
HEMADO-mediated internalization of A3-YFP suggests the
involvement of different downstream signalling pathways to
stimulate receptor internalization and to test this, cells
expressing A3-YFP or A3 W243F-YFP were treated with PTx
for 16 h before stimulation to prevent coupling to Gi/o G-
proteins. Pretreatment of A3-YFP- or A3 W243F-YFP-
expressing cells with PTx resulted in no change in the
potency of NECA (pEC50 values in the presence of PTx of 5.58
± 0.31 and 6.29 ± 0.11 for A3-YFP and A3 W243F-YFP, respec-
tively; n = 4, P > 0.05, Student’s unpaired t-test vs. pEC50
values in the absence of PTx) (Figure 3). In addition, PTx
treatment did not alter the distribution of either receptor
before or after agonist treatment (data not shown). The
influence of PTx treatment on the concentration-response
characteristics of HEMADO-mediated internalization of the
wild-type A3-YFP receptor is shown in Figure 3. In contrast to
NECA-mediated A3-YFP receptor internalization, pretreat-
ment with PTx significantly reduced the extent of HEMADO-
stimulated internalization. There was a pronounced decrease
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Figure 1
NECA, but not HEMADO, treatment stimulates internalization of A3 W243F-YFP. (A) Confocal images of A3-YFP (top panels) and A3 W243F-YFP-
expressing (bottom panels) cells were obtained in the absence of agonist (left-hand panels), and both receptors showed predominately membrane
expression. After a 30 min treatment with 10 μM NECA (middle panels) or 10 μM HEMADO (right hand panels), fluorescent granules were
observed within both A3-YFP- and A3 W243F-YFP-expressing cells upon NECA treatment with not with HEMADO. Images are representative of
those obtained in three separate experiments. (B) Chemical structures of the agonists NECA and HEMADO. (C) Fluorescent intensity values
(expressed as a percentage of the wild-type control) were determined for YFP in membrane regions of interest (ROIs) for control (basal), 10 μM
NECA and 10 μM HEMADO images obtained in (A). Each bar represents the mean ± SEM of membrane ROIs obtained from at least 55 different
cells. ***P < 0.001; n.s., not significant, according to one-way ANOVA with Dunnett’s post hoc analysis.
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in the maximal levels of internalization in the presence of
PTx (30 ± 6% reduction vs. 10 μM NECA internalization, n =
5) but no significant change in the potency of the agonist
(pEC50 = 6.55 ± 0.21, n = 5).
By introducing the W243F mutation to the A3 receptor, it
is possible that ligand-binding site has been sufficiently
altered to prevent the binding of HEMADO to the receptor.
To confirm that HEMADO was still capable of binding to
the A3 W243F-YFP receptor, we investigated the affinity of
NECA and HEMADO at both A3-YFP and A3 W243F-YFP recep-
tors using a previously characterized fluorescence-based com-
petition binding assay, using an xanthine amine congener-
based fluorescent antagonist, CA200645 (Stoddart et al.,
2012). Initially, we established that the fluorescent antagonist
used in the competition binding assay, CA200645, itself
retained affinity at both A3-YFP and A3 W243F-YFP. This was
achieved by measuring the shift in NECA internalization
concentration-response curves at both A3-YFP and A3 W243F-
YFP in the presence of 25 nM CA200645 (Supporting Infor-
mation Figure S2). Subsequent Gaddum analysis revealed the
pKD for CA200645 was 7.82 ± 0.13 at the A3-YFP receptor and
7.81 ± 0.05 at the A3 W243F-YFP receptor. A3-YFP and A3
W243F-YFP cells were treated with increasing concentrations
of NECA or HEMADO in the presence of 25 nM CA200645,
automated confocal images were obtained on the Ultra con-
focal plate reader and total image intensities were deter-
mined. As shown in Figure 4A, a concentration-dependent
decrease in CA200645 binding was observed with both NECA
and HEMADO in both cell lines. Calculation of pKi values
from the resulting IC50 values showed that the affinity of both
NECA and HEMADO was similar at both wild-type and
mutant receptors (Table 1). To confirm that HEMADO was
acting as an antagonist at the A3 W243F-YFP receptor (com-
pared with its agonist properties at the A3-YFP receptor), A3
W243F-YFP-expressing cells were pretreated with 10 μM
HEMADO before the addition of increasing concentrations of
Figure 2
Concentration- and time-dependence of A3 W243F-YFP and A3-YFP internalization in response to NECA and HEMADO. Automated confocal
images were obtained on the ImageXpress Ultra plate reader using cells that expressed either A3-YFP or A3 W243F-YFP and granularity analysis
performed as described in methods. A3-YFP (closed circles) or A3 W243F-YFP (open circles) were exposed to increasing concentrations of NECA
(A) or HEMADO (B) for 45 min or 10 μM NECA (C) or HEMADO (D) for increasing amounts of time. The data shown represent granule count per
cell and are represented as a percentage of the 10 μM NECA response for each receptor. Each data point represents the mean ± SEM of at least
five (see Table 1) experiments performed in duplicate.
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NECA. Under these conditions, the ability of NECA to cause
internalization of the A3 W243F-YFP receptor was virtually
abolished (Figure 5).
Influence of the A3 W243F mutation
on inhibition of downstream
functional responses
We further investigated the functional consequences of this
mutation by evaluating its impact on second-messenger sig-
nalling. It is well documented that the A3 receptor can induce
phosphorylation of ERK1/2 via the activated βγ subunits of
the G-protein (Schulte and Fredholm, 2002). We observed a
robust, concentration-dependent increase in ERK1/2 phos-
phorylation in both A3-YFP- and A3 W243F-YFP-expressing
cells following a 5 min stimulation with NECA (Figure 6A).
There was no significant difference in the potency of NECA at
A3-YFP and A3 W243F-YFP receptors (Table 2, P > 0.05, Stu-
dent’s unpaired t-test), but the maximal increase in ERK1/2
phosphorylation was significantly reduced in the A3 W243F-
YFP cells (P < 0.05, Student’s unpaired t-test). Unexpectedly,
HEMADO also caused a concentration-dependent increase in
ERK1/2 in both A3-YFP- and A3 W234F-YFP-expressing
cells (Figure 6B). However, HEMADO was significantly less
potent at A3 W243F-YFP compared with A3-YFP (P < 0.05,
Student’s unpaired t-test) and showed a significantly reduced
maximum response compared with the wild-type receptor
(Table 2).
The effect of the W243F mutation on agonist-mediated
changes in cAMP were also investigated via two independent
methods: firstly, by direct measurement of [3H]-cAMP levels
and secondly, by cAMP-mediated activation of a reporter
gene. The A3 receptor couples predominately to the Gi family
of G-proteins, causing an inhibition of FSK-stimulated
cAMP production. In A3-YFP-expressing cells, stimulation
with either NECA or HEMADO for 1 h caused a substantial
concentration-dependent inhibition of FSK-stimulated [3H]-
cAMP accumulation (Figure 7A,B), with HEMADO acting as a
full agonist at this response compared with NECA. In
A3 W234F-YFP-expressing cells, NECA and HEMADO also
Figure 3
Effect of PTx treatment on NECA- and HEMADO-mediated A3-YFP internalization. A3-YFP- (A and B) or A3 W243F-YFP-expressing (C) cells were
treated with (open symbols) or without (closed symbols) PTx overnight (100 ng·mL−1). Cells were stimulated with increasing concentrations of
NECA (A and C) or HEMADO (B). Automated confocal images on the ImageXpress Ultra plate reader were obtained and granularity analysis
preformed as described in methods. The data shown represent granule count per cell and are represented as a percentage of the 10 μM NECA
response. Each data point represents the mean ± SEM of three (A), five (B) and four (C) experiments performed in triplicate.
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induced inhibition of FSK-stimulated [3H]-cAMP accumula-
tion, but the maximum response was reduced relative to
A3-YFP-expressing cells (Table 2). In order to compare results
directly with those from the reporter gene assay, [3H]-cAMP
accumulation was also carried out using a 5 h stimulation
time. In cells expressing the A3-YFP receptor, a similar
response was seen to that using a 1 h stimulation for both
agonists, in terms of both potency and maximum effect, (P >
0.05, Student’s unpaired t-test) (Figure 7C,D). In contrast, for
the A3 W243F-YFP receptor, while 1 h treatment with both
NECA and HEMADO lead to a moderate inhibition of FSK-
stimulated cAMP accumulation (49.7 ± 2.0% and 43.2 ± 4.3%
inhibition, respectively) (Table 2), extending the agonist
stimulation time to 5 h reduced the maximal inhibition of
cAMP accumulation (Figure 7). This reduction in response
following a 5 h agonist exposure was muchmore pronounced
with HEMADO, with very little inhibition of [3H]-cAMP accu-
mulation seen compared with the levels of inhibition
observed after 1 h of agonist stimulation.
Both A3-YFP and A3 W243F-YFP cell lines also expressed a
SPAP reporter gene, linked to a CRE-promoter (Baker et al.,
2002), which gives an indirect measure of cAMP levels. NECA
stimulation (5 h) caused a concentration-dependent inhibi-
tion of SPAP production in response to 3 μM FSK in both the
wild-type A3-YFP and A3 W243F-YFP receptor-expressing cells.
As with the [3H]-cAMP accumulation assays, the maximum
inhibition achieved was substantially reduced in A3W234F-
YFP cells compared with that in A3-YFP cells (30 ± 4% inhi-
bition for A3 W243F-YFP vs. 79 ± 7% for A3-YFP) (Figure 8A,
Table 2). As shown in Figure 8, HEMADO showed similar
efficacy to NECA in cells expressing the wild-type A3-YFP.
However, in A3 W243F-YFP-expressing cells, HEMADO caused
no significant decrease in FSK-stimulated SPAP production at
any concentration of agonist tested (Figure 8B, Table 2). To
confirm that the inhibition of SPAP production in A3-YFP and
A3 W243F-YFP cells was Gi/o-mediated, cells were treated with
PTx and NECA concentration-response curves were generated
in the presence and absence of FSK. In both cell lines, pre-
incubation with PTx abolished NECA-mediated inhibition of
Figure 4
Measuring NECA and HEMADO affinity at A3-YFP and A3 W243F-YFP using a fluorescence-based competition binding assay. A3-YFP (closed circles)
and A3 W243F-YFP (open circles) cells were treated with 25 nM of the fluorescent A3 receptor antagonist CA200645 in addition to increasing
concentrations of NECA (A) or HEMADO (B) and automated confocal images of the BY630/650 containing fluorescent ligand obtained. Data are
normalized to image intensity in the absence of competing ligand and to the image intensity obtained in the presence of 10 μM NECA for each
cell line. Each data point represents the mean ± SEM of four experiments performed in triplicate.
Figure 5
HEMADO pretreatment inhibits NECA-mediated internalization of A3
W243F-YFP. Cells expressing A3 W243F-YFP were treated with (open
squares) or without (closed circles) 10 μM HEMADO for 30 min
before the addition of increasing concentrations of NECA for 45 min
and images were obtained automatically. Granularity analysis was
performed on the resulting images. Data shown represents granule
count per cell. Data are normalized to basal (in the absence of
agonist) and maximal internalization mediated by 10 μM NECA and
each data point represent the mean ± SEM of three experiments
performed in triplicate.
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SPAP production, suggesting that the response is mediated by
activation of Gi/o. In addition, no HEMADO-mediated
response was observed in A3-YFP cells treated with PTx
(Figure 9), and basal levels of SPAP production were unaf-
fected by PTx in both cell lines. In the absence of FSK, there
was no increase in SPAP production in the presence of NECA,
indicating that there is no measurable Gs coupling by either
receptor, and that treatment with PTx does not induce the
receptors to couple to Gs in the absence of Gi/o (data not
shown).
Interaction of A3 and A3 W243F
with β-arrestin2
Subtle differences in the efficacies of NECA and HEMADO at
the signalling pathways tested thus far, and the inability of
HEMADO to stimulate sequestration of A3 W243F-YFP from
the cell surface, raises the possibility that these agonists may
differentially recruit β-arrestin2 to the receptor. To quantify
β-arrestin2 recruitment, we used a BiFC approach to trap
receptor-β-arrestin complexes through interaction between
two fragments of venus YFP (vYFP) and subsequent visuali-
zation of the resulting mature vYFP chromophore (Rose et al.,
2010). We generated stable CHO cell lines expressing
β-arrestin2-vYnL (residues 1-173 of vYFP) in combination
with A3-vYc fusion protein (residues 155-238 of vYFP) or
A3-vYc containing the W243F point mutation (A3 W243F-
vYc). Confocal imaging of the resulting cell lines indicated
low levels of BiFC under control conditions in both A3-vYc/
β-arrestin2-vYnL and A3 W234F-vYc/β-arrestin2-vYnL cell
lines, suggesting some degree of basal receptor-β-arrestin
association (Figure 10). Both NECA and HEMADO caused a
substantial increase in BiFC fluorescence in both cell lines,
which was localized in perinuclear compartments indicating
internalized receptor-β-arrestin complexes (Figure 10). To
investigate the time- and concentration-dependence of
A3-vYc/β-arrestin2-vYnL and A3 W243F-vYc/β-arrestin2-vYnL
BiFC to both agonists, quantification of BiFC was carried out
using a MD ImageXpress Ultra confocal plate reader. NECA-
stimulated receptor β-arrestin BiFC with similar potency
in both A3-vYc/β-arrestin2-vYnL- and A3 W243F-vYc/β-
arrestin2-vYnL-expressing cells (Table 3). HEMADO also
caused a concentration-dependent increase in BiFC although
Figure 6
NECA and HEMDAO mediated ERK1/2 phosphorylation via A3-YFP and A3 W243F-YFP. A3-YFP CRE-SPAP (closed circles) and A3 W243F-YFP
CRE-SPAP-expressing (open circles) cells were exposed to increasing concentrations of (A) NECA or (B) HEMADO for 5 min. Levels of phospho-
rylated ERK1/2 were quantified using the SureFire AlphaScreen kit. Data were normalized to the 10 μM NECA response in A3-YFP-expressing cells.
The data shown represent the mean ± SEM of four (A) or three (B) experiments performed in triplicate.
Table 3
Summary of agonist-mediated A3-vYc and A3 W243F-vYc BiFC with β-arrestin2-vYnL
NECA HEMADO
pEC50
Maximal
BiFC (%) n t1/2 n pEC50
Maximal
BiFC(%) n t1/2 n
A3-YFP 7.19 ± 0.14 100 9 14.9 ± 1.8 6 8.19 ± 0.18 72.2 ± 7.1 7 17.7 ± 4.8 6
A3 W243F-YFP 7.15 ± 0.109 100 7 14.2 ± 4.4 11 7.97 ± 0.10 54.5 ± 6.1 7 11.5 ± 5.0 5
The pEC50, t1/2 and maximal BiFC induced by NECA and HEMADO was determined in A3-vYc and A3 W243F-vYc-expressing β-arrestin2-vYnL
cells. Maximal BiFC is expressed as a percentage of the internalization from treatment with 10 μM NECA in each cell line. Values are mean
± SEM from n separate experiments.
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with significantly reduced maximal levels of BiFC compared
with NECA (Figure 10 and Table 3). BiFC occurs rapidly when
the two fragments of the fluorescent protein are within close
proximity (Rose et al., 2010); therefore, it can be used to
examine the recruitment of β-arrestin by agonist-stimulated
receptor. Both NECA and HEMADO stimulated the formation
of receptor/β-arrestin complexes rapidly in both cell lines. In
addition, longer exposure to HEMADO did not increase the
maximal BiFC observed in both A3-vYc/β-arrestin2-vYnL
and A3 W243F-vYc/β-arrestin2-vYnL-expressing cells (%
maximal internalization vs. 10 μM NECA at 2 h, 84.3 ± 8.2
and 58.0 ± 5.8 for A3-vYc/β-arrestin2-vYnL and A3 W243F-
vYc/β-arrestin2-vYnL BiFC, respectively, P > 0.05, Student’s
unpaired t-test vs. maximal internalization at 60 min).
Discussion
The binding of an agonist to a GPCR leads to structural
changes within the TM regions allowing activation of a
G-protein, receptor internalization and desensitization. The
most conserved residues across the GPCR superfamily are
thought to play key roles in forming the active conformation
of the receptor (Katritch et al., 2013; Venkatakrishnan et al.,
2013). One such region is the CWxP motif within TM6, with
the conserved tryptophan originally reported to be in
involved in a rotomer toggle switch that is central to receptor
activation (Shi et al., 2002; Schwartz et al., 2006; Nygaard
et al., 2009; Tate and Schertler, 2009). However, recent crystal
structures of active-state GPCRs do not show rotomer
changes in this residue upon agonist activation (Katritch
et al., 2013). Nevertheless, W6.48 has been shown to have a
prominent role in ligand-dependent activation (Katritch
et al., 2013). For example, comparison of the existing GPCR
crystal structures have indicated that agonist-induced move-
ments of TM3, TM5, TM6 and TM7 are accompanied by a
rearrangement of a cluster of conserved hydrophobic and
aromatic residues leading to a rearrangement of the TM3–
TM5 interface and formation of new non-covalent contacts
between TM5 and TM6 (Deupi and Standfuss, 2011;
Figure 7
A3-YFP and A3 W243F-YFP mediated inhibition of forskolin-stimulated [3H]-cAMP accumulation after 1 h and 5 h of agonist stimulation. A3-YFP
(closed circles) and A3 W243F-YFP-expressing (open circles) cells were loaded with [3H]-adenine and then exposed to increasing concentration of
NECA (A and C) or HEMADO (B and D) for 1 h (A and B) or 5 h (C and D). Levels of [3H]-cAMP were estimated by scintillation counting after
separation by sequential Dowex and alumina chromatography. Data were normalized to basal (in the absence of FSK) and 10 μM FSK [3H]-cAMP
accumulation for each cell line. The data shown represent the mean ± SEM of four experiments performed in triplicate.
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Venkatakrishnan et al., 2013). This ‘transmission switch’
includes W6.48 (which interestingly is also located close to
the base of the binding pocket of many GPCRs) and also
involves L5.51, P5.50 and L3.40.
Here, we have studied the effect of mutating this residue
to phenyalanine within the A3 receptor (W243F) and deter-
mined its effects on the ability of the receptor to: (i) generate
a second-messenger signal; (ii) interact with β-arrestin2; and
(iii) to undergo receptor internalization.
Previous studies of the properties of the A3 receptor con-
taining a mutation in this region found the mutant receptor
unable to couple to G-proteins (Gao et al., 2002). To compare
the expression pattern and internalization characteristics of
the wild-type and mutant A3 receptor, we created YFP fusions
to allow visualization of the receptors. Initial confocal
imaging confirmed that the mutant receptor was trafficked
effectively to the cell surface, and indicated that both the
A3-YFP and A3W243F-YFP were sequestered from the cell
surface upon treatment with the NECA. Quantification of the
kinetics and concentration-dependence of this response
showed that the rate of internalization of the YFP-tagged
wild-type receptor was in agreement with previous studies
(Ferguson et al., 2002; Trincavelli et al., 2002; Gao and
Jacobson, 2008). The internalization characteristics of the
mutant receptor in response to NECA stimulation were also
similar to those of the wild-type receptor. Furthermore,
HEMADO and NECA were equally efficacious in stimulating
internalization of the wild-type receptor. However, in marked
contrast to NECA, HEMADO was completely unable to inter-
nalize the W243F mutant receptor at any concentration or
time point tested. We confirmed that the affinity of the ago-
nists was not significantly different at the mutant receptor
compared with the wild-type receptor and pretreatment with
HEMADO inhibited NECA-mediated internalization. This
confirmed that, although still able to bind to the mutant
receptor with high affinity, HEMADO was unable to stabilize
the active conformation of the W243F mutant receptor
responsible for internalization.
The complete loss in efficacy of HEMADO at the mutant
A3 receptor W243F for receptor internalization was not
observed to the same extent when other second-messenger
pathways were examined. HEMADO retained an ability to
activate ERK1/2 phosphorylation and to inhibit FSK-
stimulated cAMP accumulation via A3 receptor W243F, albeit
with a lower maximal response compared with the wild-type
A3 receptor. The maximal pERK1/2 and cAMP responses
obtained for NECA and HEMADO were not significantly dif-
ferent in the W243F A3 receptor cells. However, it was notice-
able that theW243F mutation caused a significant decrease in
the potency of HEMADO for both pERK1/2 and cAMP
responses (consistent with a reduction in efficacy) while the
potency of NECA was not altered to the same degree.
This suggests that the W243F mutation has resulted in a
greater reduction in the efficacy of HEMADO for all responses
measured compared with NECA. The data also suggest that
the differences in agonist efficacy cannot be simply explained
by any differences in receptor expression levels between the
two cell lines. The smaller pERK1/2 and cAMP responses
obtained with both HEMADO and NECA are also in agree-
ment with data obtained in a variety of other GPCRs in which
the substitution of the conserved typtophan in TM6 also
resulted in a small agonist response (Wess et al., 1993; Holst
et al., 2010). In other receptors, mutations of this residue
increased receptor efficacy (bradykinin B2 receptor; Marie
et al., 2001) or converted bovine rhodopsin to a light-
insensitive mutant (Ridge et al., 1992). This confirms that this
residue plays a key role in determining the balance between
active and inactive states of the receptor.
It was noticeable that responses measured over a longer
time course (5h [3H]-cAMP accumulation or CRE-SPAP
reporter gene expression) were more sensitive to the influ-
ences of the W243F mutation, with HEMADO affected to a
greater extent than NECA. As the stimulation of CRE-driven
transcription of the SPAP gene requires a small but sustained
increase in the levels of intracellular cAMP (Baker
et al., 2004), the absence of a response to HEMADO in the
Figure 8
NECA, but not HEMADO, can stimulate a decrease in forskolin-stimulated SPAP production via A3 W243F-YFP. A3-YFP CRE-SPAP (closed circles) and
A3 W243F-YFP CRE-SPAP-expressing (open circles) cells were exposed to increasing concentrations of NECA (A) or HEMADO (B) in the presence
of 3 μM FSK and the levels of SPAP produced monitored. Data were normalized to basal (in the absence of FSK) and 3 μM FSK SPAP production
for each cell line. The data shown represent the mean ± SEM of five (A) and eight (B) experiments performed in triplicate.
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CRE-driven gene transcription assay compared with the 1h
[3H]-cAMP assay suggests that there are differences in the
sustained nature of the Gi-mediated inhibitory signal gener-
ated in A3 receptor W243F cells in response to HEMADO and
NECA. This is consistent with the data obtained on [3H]-
cAMP accumulation after 5 h and provides some evidence
that receptor internalization may be required for sustained
signalling to Gi. Interestingly, a requirement of receptor
internalization for sustained signalling to the cAMP
pathway has been observed for a number of other
GPCRs (Mullershausen et al., 2009; Feinstein et al., 2011;
Werthmann et al., 2012; Irannejad et al., 2013).
It is becoming clear that certain ligands can bias intracel-
lular signalling to particular pathways (Kenakin, 2012). For
example, propranolol can act as an inverse agonist of
β2-adrenoceptor-mediated cAMP accumulation but as an
agonist of β2-adrenoceptor-mediated pERK1/2 pathways
within the same cells (Azzi et al., 2003; Baker et al., 2003).
Differences in the ability of agonists to translocate β-arrestin
and signal to the cAMP pathway via the A3 receptor have been
demonstrated previously (Gao and Jacobson, 2008). The com-
plete loss of the ability of the W243F A3 receptor to internal-
ize in response to HEMADO (under conditions where the
response to NECA is unaffected) therefore raises the possibil-
ity that this ligand may bias signalling towards G-protein
coupled pathways in this mutant cell line.
To determine whether both NECA and HEMADO are
capable of stimulating the recruitment of β-arrestin2 to both
the wild-type A3 receptor and the mutant W243F receptor, we
used a BiFC approach previously used to study other GPCR-
β-arrestin interactions (Kilpatrick et al., 2010; Watson et al.,
2012). We observed that NECA and HEMADO induced BiFC
between β-arrestin2 and both the wild-type and W243F
mutant of the A3 receptor. The potency of NECA is in line
with that observed using enzyme fragment complementation
(EFC) based approach (Gao and Jacobson, 2008). The positive
BiFC signal relies on the close proximity of the two non-
fluorescent fragments of the vYFP, which allows their
Figure 9
Pertussis toxin treatment blocks NECA-stimulated inhibition of forskolin-activated gene expression in A3-YFP CRE-SPAP and A3-W243F-YFP
CRE-SPAP cells. The effect of PTx treatment on NECA-mediated inhibition of FSK-stimulated CRE-mediated SPAP production was evaluated in
A3-YFP CRE-SPAP (A) or A3 W243F-YFP CRE-SPAP-expressing (B) cells. Where appropriate, cells were treated overnight with normal medium (closed
circles) or medium containing 100 ng·mL−1 PTx (open squares) before stimulation with increasing concentrations of NECA in the presence 3 μM
FSK. The data shown represent the mean ± SEM of four experiments performed in triplicate.
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Figure 10
Visualization and quantitative analysis of agonist-stimulated A3 receptor or A3 W243F receptor BiFC with β-arrestin2. (A) Confocal images of
A3-vYc/β-arrestin2-vYnL- (top panels) and A3 W243F-vYc/β-arrestin2-vYnL- (bottom panels) expressing cells were obtained in the absence
(left-hand panels) of agonist. Cells were stimulated with 10 μM NECA (middle panels) or 10 μM HEMADO for 60 min (left-hand panels). Images
were obtained using a Zeiss 710 confocal microscope and are representative of those obtained in three separate experiments. Quantitative analysis
of agonist-stimulated BiFC was carried out on images obtained from the ImageXpress Ultra confocal plate reader. A3-vYc/β-arrestin2-vYnL (closed
symbols) and A3 W243F-vYc/β-arrestin2-vYnL- (open symbols) expressing cells were stimulated with increasing concentrations of (B) NECA or (C)
HEMADO for 60 min before imaging and automated image analysis as described in the Methods section. To examine the time course of BiFC
formation, A3-vYc/β-arrestin2-vYnL (closed symbols) and A3 W243F-vYc/β-arrestin2-vYnL- (open symbols) expressing cells were stimulated with
10 μM NECA (D) or HEMADO (E) for increasing amounts of time (2.5–120 min). Each data point represents the mean ± SEM of at least five
separate experiments performed in triplicate.
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interaction and refolding to generate the mature chromo-
phore which can be measured as vYFP fluorescence (Rose
et al., 2010). BiFC and EFC can measure transient interactions
between two proteins but it is important to note that the
complementation of the two fragments is essentially irrevers-
ible (Morell et al., 2007). This effectively means that A3
receptor-β-arrestin2 complexes will be trapped by the BiFC
process once they have been formed. The differences
observed in the efficacy of HEMADO for the A3 receptor
W243F mutant between the quantitative imaging of receptor
internalization and the β-arrestin BiFC approaches may,
therefore, be due to the overexpression of β-arrestin2 in the
BiFC cell line, which may amplify the receptor-arrestin inter-
action and trap the receptor in A3 receptor-β-arrestin2 com-
plexes that then enhance A3 receptor internalization. It is also
worth noting, however, that A3-vYc fused protein is smaller
that A3-YFP and this might therefore allow more efficient
coupling of the W243F A3 receptor to β-arrestin2 following
stimulation with HEMADO. Finally, it may also be that the
interaction of the HEMADO-bound mutant receptor and
β-arrestin2 in the W243F cell line (in the absence of
β-arrestin2 overexpression) is normally transient and not
long enough to facilitate receptor internalization. What is
clear, however, is that HEMADO has a lower efficacy than
NECA for this A3 receptor-β-arrestin2 interaction and that the
W243F mutation further reduces this efficacy in comparison
with NECA. Variations in β-arrestin recruitment by different
agonists have been observed for other GPCRs (Hoffmann
et al., 2008; Shukla et al., 2008). For example, activation
of the P2Y2 receptor by ATP or UTP has been shown to
induce differential coupling to β-arrestin1 and β-arrestin2
(Hoffmann et al., 2008).
Our data on the A3 receptor W243F mutant supports the
idea that this residue is important in forming the active
conformation of the receptor to stimulate a variety of down-
stream signalling pathways. W6.48 appears in many GPCRs
to be an important residue as part of a ‘transmission switch’
in mediating the transition between the active and inactive
conformation of the receptor (Deupi and Standfuss, 2011;
Katritch et al., 2013; Venkatakrishnan et al., 2013). Biophysi-
cal techniques have shown that, in rhodopsin and the
β2-adrenoceptor, TM6 undergoes large conformational
changes upon activation (Farrens et al., 1996; Gether et al.,
1997; Yao et al., 2006). The crystal structure of the adenosine
A2A receptor bound to an agonist demonstrates that the
agonist induces a shift in the position of W197 (W6.48)
which causes TM6 to tilt and rotate (Xu et al., 2011), and
although not as pronounced, there is also a shift in the
position of W6.48 in the nanobody-stabilized active confir-
mation of the β2-adrenoceptor (Rasmussen et al., 2011). It has
been suggested that agonist binding causes movement of the
TM backbone and the change in position of W6.48 induces
the conformational change of TM6 that is important in
receptor activation (Xu et al., 2011).
Our data support a central role of W6.48 in the agonist-
induced activation of Gi protein and β-arrestin2 pathways via
the A3 receptor, but also raise the prospect that individual
agonists elicit different changes in the position of this residue
with consequent implications for their ability to activate
Gi-coupling and receptor internalization. These studies
suggest that conformational changes in TM6 in the region of
W6.48 may have an important role in determining the struc-
tural basis of agonist efficacy and ligand bias in activating
intracellular signalling.
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Figure S1 Internalization of SNAP-labelled A3 and A3 W243F.
Confocal images of cells transiently expressing SNAP-A3 (top
panels) and SNAP-A3 W243F (bottom panels) and labelled
with SNAP-surface BG-AF488 were obtained in the absence of
agonist (left-hand panels), and both receptors showed pre-
dominately membrane expression. After a 30 min treatment
with 10 μM NECA (middle panels) or 10 μM HEMADO (right
hand panels), fluorescent granules were observed within both
SNAP-A3- and SNAP-A3 W243F-expressing cells upon NECA
treatment with granules only observed with in HEMADO
treated SNAP-A3 cells. Images are representative of those
obtained in three separate experiments.
Figure S2 Measuring CA200645 affinity at A3-YFP and A3
W243F-YFP. A3-YFP- (A) or A3 W243F-YFP-expressing (B) cells
were treated with increasing concentrations of the agonist
NECA after pretreatment with (open circles) or without
(closed circles) 25 nM of the fluorescent antagonist
CA200645. Cells were fixed and images were collected on the
IX Ultra confocal plate reader and automated granularity
analysis performed on the resulting images. Data were nor-
malized to basal (absence of NECA) and 10 μM NECA
responses for each cell line. Each data point represents mean
± SEM from five experiments performed in triplicate.
Gaddum analysis of the CA200645-induced shift in the NECA
concentration-response curves was performed and the calcu-
lated pKB of CA200645 for A3-YFP was 7.82 ± 0.13 and 7.81 ±
0.05 for A3 W243F-YFP.
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